Dr. Sammy Elmariah | UCSF Health

Dr. Sammy Elmariah, MD

Claim this profile

Massachusetts General Hospital

Studies Cardiovascular Disease
Studies Von Willebrand Disease
13 reported clinical trials
18 drugs studied

Affiliated Hospitals

Image of trial facility.

Massachusetts General Hospital

Image of trial facility.

University Of California, San Francisco

Clinical Trials Sammy Elmariah, MD is currently running

Image of trial facility.

PFO Closure Device

for Preventing Stroke

This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.

Recruiting

1 award

N/A

3 criteria

Image of trial facility.

Proteomics Analysis

for Heart Valve Disease

The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT. The study population will be adult patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration. Enrollment will continue until 30 patients with HALT are identified for completion of phase 1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients. Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0), post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the occurrence of HALT. Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which point a follow-up CT scan and blood sample will be obtained. Control subjects will also undergo a 6-month study visit with blood sample collection. The study will be conducted within two phases. Phase 1 will serve as a derivation / discovery study in which candidate protein biomarkers of HALT will be identified. Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2 will be performed under the auspices a future contract or amendment and will seek to cross-validate the initial study findings.

Recruiting

1 award

Phase 1

3 criteria

More about Sammy Elmariah, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Sammy Elmariah, MD has experience with

  • Edwards PASCAL System
  • Optimal Medical Therapy
  • Decision Aid
  • Shared Decision Making Skills Training
  • Tendyne Mitral Valve System
  • MitraClip System

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sammy Elmariah, MD specialize in?

Is Sammy Elmariah, MD currently recruiting for clinical trials?

Are there any treatments that Sammy Elmariah, MD has studied deeply?

What is the best way to schedule an appointment with Sammy Elmariah, MD?

What is the office address of Sammy Elmariah, MD?

Is there any support for travel costs?